arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Senti Biosciences Holdings, Inc.

SNTI
$0.16 ▼ -0.01 (-7.90%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
23 Visible periods
23 Metrics
Absolute Benchmarks
Price Chart
38
Health
Weak
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Senti Biosciences Holdings, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $5.0M
Dividend Yield —
Revenue Growth None
Op. Margin —
ROIC 336.6% ↗
FCF / Share $-0.46 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

23-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$17.00K
↑ +6.2% —
Net Income Profit after all expenses
$-4.22M
↑ +70.1% —
FCF / Share Free cash flow per share
$-0.46
↓ -89.4% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -972.2% is weak on an absolute basis (target > 10%)
  • FCF / Net IncomeFCF / Net Income of 0.71x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality →
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 6 years · 23 quarters